AstraZeneca (LON:AZN) Given “Buy” Rating at Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by equities researchers at Jefferies Financial Group in a research report issued to clients and investors on Wednesday, Digital Look reports. They currently have a £175 price objective on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target points to a potential upside of 45.57% from the stock’s previous close.

Several other equities analysts also recently commented on the stock. Citigroup increased their target price on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Berenberg Bank reissued a “buy” rating and issued a £175 price target on shares of AstraZeneca in a research report on Wednesday. Royal Bank Of Canada reissued an “outperform” rating and set a £145 target price on shares of AstraZeneca in a research report on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 price target on shares of AstraZeneca in a report on Tuesday, September 29th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus target price of £153.57.

AstraZeneca Stock Performance

Shares of AZN opened at £120.22 on Wednesday. The company’s fifty day moving average is £120.93 and its 200-day moving average is £132.33. AstraZeneca has a 12 month low of GBX 119.20 and a 12 month high of £157.32. The firm has a market cap of £186.45 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10.

Insider Buying and Selling

In related news, insider Michel Demare acquired 2,500 shares of the firm’s stock in a transaction on Monday, September 14th. The shares were bought at an average cost of £121.21 per share, with a total value of £303,025. 0.15% of the stock is currently owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.